Business Wire

MD-IPROOV

7.6.2022 09:02:10 CEST | Business Wire | Press release

Share
What Does the Future of Travel Look Like? A Majority of Consumers Favor a Journey Straight from the Couch to the Gate

As the summer travel season kicks off, consumers are ready to take to the skies to get away to relaxing vacations. The only problem? Getting there.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005376/en/

A new consumer survey released today by iProov , the world leader in biometric face authentication technology, found that travelers do not find the airport check-in process a relaxing first step to a destination. In fact, a majority of those surveyed would prefer to streamline the process to go straight from their couch at home to the gate in as few steps as possible.

Eighty-five percent (85%) of the 16,000 respondents in eight countries would use or would consider using a ticket/ID check from home. Further, 70% of respondents said the first step of the journey–waiting in long check-in lines–is the most annoying part of traveling.

So, how can airports and airlines reduce the bottlenecks during journeys using check-from-home services to make the travel experience more convenient for consumers? Secure remote verification technology enables travelers to complete their ticket and ID checks from the comfort of their homes, so they don't need to do it at the airport. The key to this process is facial biometric verification and authentication.

“Secure verification technology enables travelers to complete their ticket and ID checks from the comfort of their homes, so they don't need to do it at the airport,” said Andrew Bud, Founder and CEO of iProov. “Facial biometric verification and authentication are key to this process. Face verification has already proved to be a secure and accessible solution for many applications and processes–for example, nearly a third of consumers are already using face verification to access their mobile banking apps. We’ve shown that online face verification can be applied to improve the consumer travel experience, making life easier for travelers and operators around the world.”

iProov’s Genuine Presence Assurance® offers a brief, passive face scan that confirms a remote traveler is the right person, matching the identity to a trusted identity document and ticket. The technology also verifies that the user is a real person and not a presentation attack using a photo or mask, and that they are authenticating in real time. At the airport, a traveler’s face is their ticket as they choose to pass through a biometric corridor and authenticate their identity.

This technology solution is not unique to the airline industry and can be applied to eliminate check-in bottlenecks for other forms of travel, including trains, cruise ships, car hires and more. In fact, earlier this year, iProov partnered with Eurostar for the successful trial of a remote fast-track service, SmartCheck, showing that the future of travel is not so distant.

To learn more about iProov and the future of travel, please visit the Biometric Travel & Check-In section of our website.

Methodology

This report is based on research carried out by an independent agency on behalf of iProov in April–May 2022. Eight countries were included in the research (the U.S., Canada, Mexico, Germany, Italy, Spain, the UK and Australia), with 2000 consumers surveyed in each country. The 16,000 respondents were not chosen for any preferences on travel–many had never flown before.

About iProov

Launched in 2013, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING, and others. iProov’s technologies include Liveness Assurance™ and Genuine Presence Assurance® , which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks and the emerging threat of deepfakes. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release

Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm

Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release

- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno

The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release

New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights

Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 08:00:00 CEST | Press release

From dating apps to financial details, respondents report seeing a wide range of highly personal information on others' screens 56% of people admit to having looked at strangers’ phone screens accidentally, whereas 24% have done so out of curiosity. 57% identify public transport as the most likely place to notice someone else's screen. While 48%* feel confident they can keep their phone activity private when using it in crowded places, another 52%** acknowledge it is easy to see someone’s screen who is next to you in a public place without trying to look. 33% say they have seen personal content on a stranger’s phone in public. Some smartphone users who have looked at a stranger’s phone screen in public ignore and continue what they were doing (28%) or look away immediately (27%), but others (7%) admit to continuing to look discreetly. The new Samsung Galaxy S26 Privacy Display1 limits side-angle viewing of your screen to protect your privacy in any setting. As millions of Europeans2 ge

RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release

A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye